Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA animal data efficacy rule

This article was originally published in The Tan Sheet

Executive Summary

Drugs may be approved for human use based solely on animal data in cases where human testing is not feasible or ethical, according to FDA final rule published in May 31 Federal Register. Under the reg, drugs used "to reduce or prevent the toxicity of chemical, biological, radiological or nuclear substances" may be approved for marketing "based on evidence of effectiveness derived only from appropriate animal studies and any additional supporting data," agency says. Reg is part of FDA's effort to help improve nation's ability to respond to emergencies, including terrorist events; notice comes shortly after Congress passed bioterrorism bill (1"The Tan Sheet" May 27, 2002, p. 18)...

You may also be interested in...



Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill

Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS094086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel